The Orphan Medicines Industry Group (OMIG) is a group of pharmaceutical companies that are members of the ABPI working together for the benefit of patients with rare diseases in the UK.
OMIG is working closely with stakeholders to ensure that people in the UK with rare diseases get access to the orphan medicines they need in order to improve health outcomes for all patients with rare diseases.
Objectives of OMIG
People with rare disease get access to the licensed orphan medicines in the UK now and in the future by:
What are orphan medicines?
Orphan medicines are medicines used to treat rare conditions. They are defined as innovative treatments in an area of unmet need for rare but serious diseases with a typical prevalence of less than five per 10,000 population.1
In order to be granted orphan medicine status by the European Union (EU), companies must demonstrate that:
The disease or conditions for which the medicinal product would be administered affects not more than five in 10,000 persons in the community at the time at which the application for designation is submitted.
The disease or condition should be of a life-threatening or chronically debilitating nature.
Without incentives it is unlikely that the marketing of the medicinal product in the community would generate sufficient return to justify the necessary investment.
There exists no satisfactory method of diagnosis, prevention or treatment of the condition in question, or if such method exists, the medicinal product will be of significant benefit to those affected by that condition.2